search
Back to results

Model-based Versus Traditional Warfarin Dosing in Children (WATCH)

Primary Purpose

Congenital Heart Defects

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Warfarin Dosing Aid
Standard Practice
Sponsored by
De Montfort University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Congenital Heart Defects

Eligibility Criteria

1 Day - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: -Children from birth up to 18 years with congenital heart disease who have been treated or to be treated with warfarin after undergoing reconstructive heart surgery at Glenfield Hospital, Leicester, United Kingdom.

Exclusion Criteria:

  1. Patients aged over 18 years who are treated as 'adults'.
  2. Children who refuse assent, parents who refuse consent.
  3. Any significant disease or disorder which, in the opinion of the direct care team, may either put the participant at risk because of study participation or adversely affect the participants' ability to participate in the study.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Warfarin dosing aid

    Standard practice

    Arm Description

    A pharmacokinetic/pharmacodynamic model-based dosing algorithm for warfarin.

    Dosing adjustments according to the normal unit protocol

    Outcomes

    Primary Outcome Measures

    The difference between the model based and traditional warfarin dosing method in International Normalised Ratio (INR) response.
    INR response includes: Time taken (days per patient) to achieve stable anticoagulation within the desired therapeutic range (TR), number and percentage of INR measurements within the TR, Time in TR, and frequency of INR measurements (number of INR measurements per month) per patient.

    Secondary Outcome Measures

    Medical staff perceptions of value of warfarin dosing aid
    Interviews with medical staff will be conducted
    Patients or carers 'lived experience' of monitoring warfarin dosing and INR
    Interviews will be conducted with patients and or carers
    The incidence of warfarin-related adverse events, bleeding and bruising, by recording on symptom diary cards

    Full Information

    First Posted
    June 12, 2015
    Last Updated
    June 19, 2015
    Sponsor
    De Montfort University
    Collaborators
    University Hospitals, Leicester
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02475863
    Brief Title
    Model-based Versus Traditional Warfarin Dosing in Children
    Acronym
    WATCH
    Official Title
    A Study to Compare Model-based Warfarin Dosing to the Traditional Approach in Children After Congenital Heart Surgery at Glenfield Hospital, Leicester
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2015
    Overall Recruitment Status
    Unknown status
    Study Start Date
    August 2015 (undefined)
    Primary Completion Date
    August 2016 (Anticipated)
    Study Completion Date
    January 2018 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    De Montfort University
    Collaborators
    University Hospitals, Leicester

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This study compares the clinical effectiveness of a new algorithm (model-based warfarin dosing) with standard practice (doctor's own judgement and intuition) designed to determine the most appropriate anticoagulant dose of warfarin in children after congenital heart surgery.
    Detailed Description
    Warfarin is widely used in children after heart surgery in order to prevent complications that may arise due to blood clots forming in unwanted places - for example in the brain causing a stroke. If too little warfarin is given, there is a risk that clots may form. If the dose is too high, bleeding will result. Traditionally, the approach to dosing warfarin in children has been to select a starting dose according to standard guidelines and to then adjust the doses for each child by monitoring the INR (which measures how quickly blood clots). However, a person's make up as well as external factors, such as age, weight, diet and genetics can affect warfarin dosing and this makes controlling the dose and hence controlling the INR, more difficult. Recently however, a more sophisticated dosing model has been developed by researchers which takes into account some of these factors. The model is designed to help doctors select the best dose of warfarin for children by individualising prescriptions. The aim of the proposed research is, therefore, to compare the model based warfarin dosing with the traditional approach to warfarin dosing in children who have undergone congenital heart surgery. The research will involve children who are started on warfarin for the first time and also children who are already receiving ongoing warfarin therapy.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Congenital Heart Defects

    7. Study Design

    Primary Purpose
    Supportive Care
    Study Phase
    Not Applicable
    Interventional Study Model
    Crossover Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    45 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Warfarin dosing aid
    Arm Type
    Experimental
    Arm Description
    A pharmacokinetic/pharmacodynamic model-based dosing algorithm for warfarin.
    Arm Title
    Standard practice
    Arm Type
    Active Comparator
    Arm Description
    Dosing adjustments according to the normal unit protocol
    Intervention Type
    Device
    Intervention Name(s)
    Warfarin Dosing Aid
    Intervention Description
    A pharmacokinetic/pharmacodynamic model-based dosing algorithm for warfarin
    Intervention Type
    Other
    Intervention Name(s)
    Standard Practice
    Intervention Description
    Warfarin dose adjustments according to standard unit protocol
    Primary Outcome Measure Information:
    Title
    The difference between the model based and traditional warfarin dosing method in International Normalised Ratio (INR) response.
    Description
    INR response includes: Time taken (days per patient) to achieve stable anticoagulation within the desired therapeutic range (TR), number and percentage of INR measurements within the TR, Time in TR, and frequency of INR measurements (number of INR measurements per month) per patient.
    Time Frame
    6 months for warfarin naiive patients and 12 months for patients already on warfarin therapy.
    Secondary Outcome Measure Information:
    Title
    Medical staff perceptions of value of warfarin dosing aid
    Description
    Interviews with medical staff will be conducted
    Time Frame
    Within six months of end of period of data collection
    Title
    Patients or carers 'lived experience' of monitoring warfarin dosing and INR
    Description
    Interviews will be conducted with patients and or carers
    Time Frame
    Within six months of end of cross-over trial
    Title
    The incidence of warfarin-related adverse events, bleeding and bruising, by recording on symptom diary cards
    Time Frame
    6 months for warfarin naiive patients and 12 months for patients already on warfarin therapy.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    1 Day
    Maximum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: -Children from birth up to 18 years with congenital heart disease who have been treated or to be treated with warfarin after undergoing reconstructive heart surgery at Glenfield Hospital, Leicester, United Kingdom. Exclusion Criteria: Patients aged over 18 years who are treated as 'adults'. Children who refuse assent, parents who refuse consent. Any significant disease or disorder which, in the opinion of the direct care team, may either put the participant at risk because of study participation or adversely affect the participants' ability to participate in the study.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Hussain Mulla, PhD
    Phone
    0116 2563323
    Email
    hussain.mulla@uhl-tr.nhs.uk
    First Name & Middle Initial & Last Name or Official Title & Degree
    Peter Rivers, PhD
    Phone
    0116 2577039
    Ext
    7039
    Email
    privers@dmu.ac.uk
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Hussain Mulla, PhD
    Organizational Affiliation
    Univesity Hospitals Leicester NHS Trust
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Model-based Versus Traditional Warfarin Dosing in Children

    We'll reach out to this number within 24 hrs